Deena Graham, MD
Medical Oncology · Hackensack, NJNPI 1790716926
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.6%), consulting fees and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Eisai Inc. at 50.4% of the total. Reporting peaked in 2021 at $2,259 and has fallen 70.5% since, to $666 in 2025.
Across 248 payments — averaging $32.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$4K
- Novartis$979
- Daiichi Sankyo Inc.$799
- Gilead$370
- GSK$318
- AstraZeneca$291
- plus $1K from 21 others
Across 257 payments — averaging $10,484 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.3M
- Merck$561K
- Karyopharm Therapeutics Inc.$307K
- Seagen Inc.$267K
- AstraZeneca$106K
- Sanofi US Services Inc.$58K
- plus $73K from 5 others
What the payments were for
- Consulting fees$3,89048%
- Food & beverage$4,09451%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 12 | $4,077 |
| Novartis | 80 | $979 |
| Daiichi Sankyo Inc. | 39 | $799 |
| Gilead | 21 | $370 |
| GSK | 18 | $318 |
| AstraZeneca | 17 | $291 |
| Merck | 12 | $187 |
| Seagen Inc. | 6 | $176 |
| Pfizer | 9 | $148 |
| Astrazeneca UK Limited | 1 | $135 |
| AbbVie | 6 | $103 |
| Mirati Therapeutics, Inc. | 5 | $95 |
| Fennec Pharmaceuticals, Inc. | 2 | $53 |
| Genentech USA, Inc. | 3 | $44 |
| Foundation Medicine, Inc. | 1 | $44 |
| Johnson & Johnson(2 entities) | 3 | $42 |
| Apellis Pharmaceuticals, Inc. | 2 | $35 |
| Amgen | 2 | $29 |
| Novo Nordisk | 1 | $25 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $19 |
| Macrogenics, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
| Heron Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,094 in reported general payments places this provider in the 65th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 66 | $888,385 |
| IbrancePalbociclib | 40 | $636,182 |
| LenvimaLenvatinib Mesylate | 17 | $408,720 |
| LynparzaOlaparib | 32 | $375,052 |
| ZejulaNiraparib Tosylate | 11 | $205,348 |
| KisqaliRibociclib Succinate | 11 | $141,384 |
| Everolimus | 23 | $72,974 |
| EliquisApixaban | 69 | $52,012 |
| ZarxioFilgrastim-Sndz | 11 | $21,134 |
| Exemestane | 120 | $18,452 |
| Anastrozole | 736 | $15,687 |
| Letrozole | 252 | $6,630 |
| Ondansetron Hcl | 46 | $452 |
| Tamoxifen Citrate | 14 | $344 |
| Gabapentin | 27 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $19 | $888,38566 claims |
| PfizerIbrance, Eliquis | $148 | $688,194109 claims |
| Eisai Inc.Lenvima | $4,077 | $408,72017 claims |
| AstraZenecaLynparza | $291 | $375,05232 claims |
| GSKZejula | $318 | $205,34811 claims |
| NovartisKisqali | $979 | $141,38411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Hackensack
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.